BS_YY5B2XDD
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 59.13272010512483
- age_years
- 10.482
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.669
- INFLAMMATORY_RESPONSE+0.622
- TNFA_SIGNALING_VIA_NFKB+0.613
- ALLOGRAFT_REJECTION+0.608
- IL6_JAK_STAT3_SIGNALING+0.593
- COAGULATION+0.541
- KRAS_SIGNALING_UP+0.540
- COMPLEMENT+0.525
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.513
- INTERFERON_GAMMA_RESPONSE+0.495
Top 10 suppressed
- MYC_TARGETS_V2-0.508
- OXIDATIVE_PHOSPHORYLATION-0.494
- MYC_TARGETS_V1-0.427
- DNA_REPAIR-0.365
- UNFOLDED_PROTEIN_RESPONSE-0.279
- MITOTIC_SPINDLE-0.270
- PROTEIN_SECRETION-0.200
- ADIPOGENESIS-0.181
- FATTY_ACID_METABOLISM-0.156
- G2M_CHECKPOINT-0.111
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N4B1SZZH | Med | Medulloblastoma | 0.948 |
| 2 | MDT-AP-2869 | Med | Medulloblastoma | 0.947 |
| 3 | BS_S9929Z8B | Ganglioglioma | — | 0.926 |
| 4 | BS_G1Y281HX | Neuroblastoma | — | 0.925 |
| 5 | BS_W97QQYKQ | Ganglioglioma | — | 0.925 |
| 6 | MDT-AP-3331 | Med | Medulloblastoma | 0.920 |
| 7 | SRR10900576 | — | — | 0.919 |
| 8 | MNG663 | — | — | 0.919 |
| 9 | MDT-AP-2651 | Med | Medulloblastoma | 0.916 |
| 10 | MDT-AP-0363 | Med | Medulloblastoma | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.669 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.622 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.613 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.608 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.593 | Inavolisib | — uncovered |
| COAGULATION | 0.541 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.540 | Inavolisib | — uncovered |
| COMPLEMENT | 0.525 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.513 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.495 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.489 | Idelalisib | — uncovered |
| APOPTOSIS | 0.418 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.414 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.408 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.367 | Inavolisib | — uncovered |
| MYOGENESIS | 0.346 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.343 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.328 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |